No Data
Aclaris Therapeutics Announces Exclusive, Global License Agreement With Biosion, Inc., Adding Potential Best-in-Class Biologics Assets to Pipeline
BTIG Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating, Announces Target Price $8
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Maintains Target Price $3
Piper Sandler: Authorized trade is transformative, significantly raising Aclaris (ACRS.US) target price to $13.
Piper Sandler has upgraded Aclaris' rating from 'neutral' to 'shareholding', and has significantly raised the target price from $3 to $13.
Express News | Aclaris Therapeutics Inc : Jefferies Raises to Buy From Hold; Raises Target Price to $7 From $2
Aclaris Therapeutics Upgraded to Buy From Neutral at BTIG
